Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE American: MAIA) reported enrollment progress in its pivotal Phase 3 THIO-104 trial of telomere-targeting therapy ateganosine for third-line advanced non-small cell lung cancer.
According to MAIA, 29 patients have been dosed across 34 sites in 6 countries, with a target of up to 100 patients by year-end and an interim survival analysis expected in 2027. Prior Phase 2 THIO-101 data showed median overall survival of 17.8 months versus 5.8 months with chemotherapy. Ateganosine has FDA Fast Track designation and is positioned within a projected $70 billion global NSCLC market by 2030.
MAIA Biotechnology (NYSE American: MAIA) received FDA clearance of an amended IND, allowing U.S. enrollment in the expanded Phase 2 THIO-101 trial of lead candidate ateganosine for advanced third-line NSCLC.
The trial runs alongside pivotal Phase 3 THIO-104 and spans 44 sites across six countries.
MAIA Biotechnology (NYSE American: MAIA) reported insider open market share purchases by its founder and CEO Vlad Vitoc and Director Stan V. Smith.
Vitoc bought about 72,700 shares at $1.3877 and Smith about 75,000 shares at $1.336 on June 6, 2026, bringing directors and officers’ ownership to 20.46%. The company is advancing its telomere-targeting immuno-oncology platform, including the ateganosine program for advanced non-small cell lung cancer.
MAIA Biotechnology (NYSE American: MAIA) presented a Trial in Progress poster at the 2026 ASCO Annual Meeting detailing its pivotal Phase 3 THIO-104 study. The trial evaluates telomere-targeting agent ateganosine (THIO) sequenced with a checkpoint inhibitor in third-line, CPI- and chemotherapy-resistant NSCLC patients.
First dosing occurred in December 2025, with screening and enrollment ongoing in Europe and Asia.
MAIA (NYSE:MAIA) activated its first U.S. clinical site (Summit Medical Group, NJ) for the Phase 2 THIO-101 expansion in third-line non-small cell lung cancer (3L NSCLC) on April 16, 2026.
The expansion adds U.S. access (four more U.S. sites planned in 2026) to a program with 44 active sites in six countries, a $2.3M NIH grant, FDA Fast Track designation, and reported overall survival beyond 24 months for eight patients.
MAIA (NYSE American: MAIA) announced that net proceeds from its March 2026 common stock offering of $33 million are expected to fully fund its ongoing pivotal Phase 3 trial of ateganosine in third-line non-small cell lung cancer (3L NSCLC).
The FDA granted Fast Track designation for ateganosine in 3L NSCLC. THIO-104 is a global, multicenter, open-label, randomized 1:1 trial of up to 300 patients comparing ateganosine plus a checkpoint inhibitor to chemotherapy; interim Phase 3 data are expected next year.
MAIA (NYSE American: MAIA) reported that eight patients in Parts A and B of its Phase 2 THIO-101 trial for non-small cell lung cancer showed overall survival beyond two years after treatment with ateganosine sequenced with cemiplimab, with no subsequent lines of therapy.
The poster presented March 27, 2026 highlighted one 3L patient at 33 months and two dozen 2L patients with survival over 30 months; THIO-101 treated 79 patients total and Part C is enrolling up to 48 participants in Asia and Europe.
MAIA Biotechnology (NYSE American: MAIA) closed an underwritten public offering of 20,000,000 shares at $1.50 per share, generating aggregate gross proceeds of $30 million on March 4, 2026. The company granted a 30-day option for up to 3,000,000 additional shares to cover over-allotments.
Proceeds are intended to fund clinical trials and for working capital and general corporate purposes; the offering was led by healthcare-dedicated investors and existing shareholders and was sold under the company’s effective Form S-3 shelf registration.
MAIA (NYSE American: MAIA) priced an underwritten public offering of 20,000,000 common shares at $1.50 per share for aggregate gross proceeds of $30.0 million, with a 45-day option to sell up to an additional 3,000,000 shares. The offering is expected to close on March 4, 2026, subject to customary closing conditions.
MAIA intends to use net proceeds to fund clinical trials and for working capital and general corporate purposes; the offering was led by healthcare-dedicated investors and existing shareholders.
MAIA Biotechnology (NYSE:MAIA) announced on March 2, 2026 that it has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option for additional shares.
Use of proceeds is intended for clinical trials, working capital, and general corporate purposes. The offering is made from an existing Form S-3 shelf registration and is subject to market conditions and SEC filing of a prospectus supplement.